瑞普生物：五种兽药产品获农业农村部批准

Core Viewpoint - Reap Bio (300119.SZ) has recently obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs, indicating progress in its product development and regulatory approval process [1]. Group 1: New Drug Registration - Reap Bio's subsidiary, South China Agricultural University Biological Pharmaceutical Co., Ltd. (referred to as "South China Bio"), has successfully registered two diagnostic reagent products as veterinary drugs [1]. - The company has also received approval for two vaccine products after passing the production strain change review by the Ministry of Agriculture and Rural Affairs [1]. Group 2: Details of New Veterinary Drugs - The newly registered veterinary drugs include: - Recombinant Cat Interferon ω (lyophilized form) developed by Reap Bio and Zhongke Baike (Tianjin) Biopharmaceutical Co., Ltd., classified as a Class II veterinary drug [2]. - Avian Influenza Virus H7 subtype (rLN79 strain) and H5 subtype (rFJ56 strain) diagnostic reagents developed in collaboration with South China Agricultural University and other partners [2]. - The vaccine products include: - Bivalent inactivated vaccine for Avian Influenza Virus (H5 subtype) combining strains H5N6 rHN503 and H5N1 rHN504, developed by multiple institutions including South China Agricultural University [2]. - Quadrivalent inactivated vaccine for Avian Influenza Virus (H5 and H7 subtypes) combining multiple strains, also developed by South China Agricultural University and its partners [2].